Recombinant Human IL-2R alpha/CD25 Protein(HEK293), His

IL-2R alpha, also known as CD25, is a key component of the interleukin-2 receptor complex and plays a critical role in the regulation of immune responses. It is predominantly expressed on activated T cells and regulatory T cells (Tregs), influencing their proliferation, survival, and function. Research into IL-2R alpha/CD25 has gained significant attention due to its implications in various immunological disorders, including autoimmune diseases, graft-versus-host disease, and cancer. Elevated levels of CD25 are often associated with a more aggressive tumor phenotype, while modulation of its expression can potentially enhance anti-tumor immunity. Recombinant forms of IL-2R alpha/CD25 are employed in both basic research and therapeutic applications, serving as potential biomarkers for immune activation and targets for immunotherapy. Studies have focused on characterizing the molecular mechanisms underlying CD25 expression and signaling pathways, as well as the development of CD25-targeted therapies, such as monoclonal antibodies. The exploration of IL-2R alpha/CD25 provides insights into T cell regulation, with the potential to enhance therapeutic strategies for immunological diseases and improve outcomes in cancer treatment. Given the ongoing advancements in biotechnology, the production of recombinant IL-2R alpha/CD25 offers a valuable tool for elucidating its functional roles and therapeutic potential within the immune system.